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A 56-year-old woman was diagnosed at our hospital with G2adenocarcinoma of the lung (T3, N2, M1) metastatic to the
brain. Subsequently, first-line therapy with gemcitabine and
cisplatin and whole-brain radiation therapy were initiated. Be-
cause of therapy-related hardness of hearing, cisplatin had to be
replaced by carboplatin after two therapy cycles. After 4 months,
tumor progression was diagnosed by computed tomography
(CT), and consequently, third-line therapy with EGFR tyrosine
kinase inhibitor erlotinib was initiated. Contrast-enhanced CT
performed at this time included additional volume perfusion
measurement of the primary tumor (Figure 1, upper panel).
Longest tumor diameter recorded was 73.6 mm, whereas auto-
matically determined blood flow (BF), blood volume (BV), and
vessel wall permeability (PMB) in the primary tumor yielded
56/18.5/9.5 ml/100 ml tissue/min, respectively. Eight weeks
later, during ongoing therapy, repeated CT volume perfusion
showed neither significant tumor size change (longest diameter,
70.5 mm) nor signs of tumor spread, but a marked drop in BF
(28.4 ml/100 ml tissue/min), BV (10.5 ml/100 ml tissue/min),
and PMB (10.5 ml/100 ml tissue/min) assumed to represent
antiangiogenic switch induced by erlotinib therapy (Figure 1,
middle panel). Another 12 weeks later, there was still no signif-
icant change in tumor size (current longest diameter, 70.7 mm)
but further reduction of tumor perfusion parameters, BF (27
ml/100 ml tissue/min) and BV (4.5 ml/100 ml tissue/min),
whereas PMB (18 ml/100 ml tissue/min) increased (Figure 1,
lower panel). However, whole-body CT disclosed, at this time,
new osseous metastases in the cervical spine indicating tumor
progression (progressive disease), despite ongoing decrease of
tumor perfusion parameters.
Inhibitors of the EGFR tyrosine kinase have clinical effi-
cacy when given as second- or third-line therapy for advanced
NSCLC.1 Knowingly, tumor size measurements, irrespective of
their accuracy (uni-bidimensional or computer-assisted volum-
etry), are not expected to objectively reflect response to treat-
ment, at least early after treatment onset.2,3 However, because of
erlotinib impact on tumor angiogenesis, perfusion measurements
represent a reliable surrogate parameter capable of confirming
early response to EGFR inhibitors.4 Thus, preliminary results of
clinical-radiologic trials focusing on noninvasive quantification
of blood flow parameters by using dynamic contrast-enhanced
perfusion CT proved successful in demonstrating decreasing
effects of different angiogenesis inhibitors on tumor blood flow
parameters.
Herein, we present serial measurements of tumor volume
and tumor perfusion in a patient with NSCLC receiving mono-
therapy with erlotinib, using a new CT volume perfusion tech-
nique, which is able to noninvasively assess blood flow param-
eters (BF, BV, and PMB). This technique uses rapid table
movement, robust motion correction, and low-dose energy pa-
rameters, thus overcoming classic sampling errors that were
inherent in earlier tumor perfusion protocols addressing only
limited tumor regions (slices) caused by technical CT limita-
tions. Perfusion analysis of the primary tumor in our patient
expectedly demonstrated marked decrease in tumor perfusion
during erlotinib therapy persisting even after tumor progression
was confirmed at other sites. Interestingly, tumor size did not
change significantly at follow-up, which is going along with
current data regarding the impact of targeted therapies on tumor
volume.
Therefore, acquisition of functional data is imperative
in these cases. However, they only represent a useful adjunct
to whole-body investigational protocols, which are still re-
quired for correct evaluation of the course of the disease.
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FIGURE 1. Axial contrast-enhanced
computed tomography examina-
tions of the chest displaying a large
bronchial carcinoma in the right
upper lobe at the level of the as-
cending aorta (long arrow, left up-
per panel). At baseline (upper row),
color maps reflecting BF and BV
demonstrated nearly homogeneous
(arrow), strong tumor perfusion (mi-
cro vessel density) with no macro-
scopic necrosis. The color scale at
the right side shows perfusion inten-
sity declining from the top (red) to
the bottom (violet). At the first fol-
low-up (middle panel), erlotinib-
induced hypoperfusion of the tumor
core is seen (arrow). At the second
follow-up (lower panel), perfusion
CT disclosed almost global hypoper-
fusion of the mass (arrow) after on-
going erlotinib therapy. Note that
tumor size did not change signifi-
cantly with time.
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